Induction of humoral immune responses and inhibition of metastasis in mice by a VEGF peptide-based vaccine

Faezeh Soltanpour Gharibdousti 1,2, Banafsheh Fazeli Delshad 1,2, Reza Falak 2, Nasrin Shayanfar 3, Mazdak Ganjalikhani Hakemi 1, Alireza Andalib 1, Gholam Ali Kardar 4*

1Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
2Immunology Research Center, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
3Department of Pathology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
4Immunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, Tehran, Iran

**Corresponding author:** Gholam Ali Kardar. Immunology, Asthma and Allergy Research Institute, Tehran University of Medical Sciences, Tehran, Iran. Tel: +98-2161472147; Email: gakardar@tums.ac.ir

Abstract

**Objective(s):** Blocking of vascular endothelial growth factor (VEGF) plays a pivotal role in inhibition of metastasis and is a target for development of anti-angiogenic agents. In this study, a peptide-based vaccine was designed and its potential for induction of humoral immune responses, generation of neutralizing antibodies, inhibition of tumor growth and metastasis was determined.

**Materials and Methods:** With online bioinformatics tools, a fragment of the VEGF-A was selected for a peptide-based vaccine. To enhance its antigenicity, the peptide was conjugated with Keyhole limpet hemocyanin and used to immunize mice. Then, the polyclonal anti-VEGF antibody titer was measured and its effect on proliferation of HUVEC cell line was investigated by MTT assay. Finally, we checked the effect of the peptide on tumor growth, metastasis, and survival rates in a mouse model of cancer.

**Results:** The bioinformatics analysis of the selected region confirmed dissimilarity of the peptide with any other human protein and its acceptable antigenicity to stimulate a tumor-specific humoral response. Anti-VEGF antibody titers were significantly greater in vaccinated mice than in controls. IgG antibody from mice immunized with recombinant VEGF-A inhibited HUVEC proliferation (P<0.0001). Tumors in vaccinated mice were significantly smaller than those in controls. Moreover, metastasis was reduced and survival rates increased in the vaccinated group.

**Conclusion:** Production of high-titer antibody against the peptide vaccine indicated that the peptide has the potency to be used as a peptide-based vaccine for humoral inhibition of tumor growth and metastasis. The efficacy of the peptide should be further tested in primate models.

Introduction

Angiogenesis is an essential process in the development and growth of tumor tissue. In the absence of this process, tumors will not grow beyond two mm3 in size. Thus, inhibition of angiogenesis is a basic strategy in cancer vaccination approaches (1, 2). Sprouting of angiogenesis is regulated by various key agents such as vascular endothelial growth factor (VEGF), which is highly expressed and continuously secreted from most solid tumors, and demonstrates both autocrine and endocrine characteristics (3-5). Therefore, inhibition of angiogenesis via blockage of VEGF signaling could suppress promotion of solid tumors (6). Currently, several anti-angiogenic approaches, especially anti-VEGF drugs have been approved by international committees for certain advanced cancers; some have been applied in clinical trials, while others are under further evaluation or await approval (2). It has been previously shown that the functionality of VEGF/VEGFR could be directly blocked by various antibodies such as Bevacizumab (Avastin®) and Ramucirumab (Cyramza®), or trapped by soluble VEGF receptors such as Aflibercept (Zaltrap®) (7, 8), or indirectly blocked by inhibiting receptor activity by specific antibodies or administration of the inhibitors of tyrosine kinase receptor. In this regard, clinical application of Sunitinib (Sutent®), Sorafenib (Nexavar®), and Pazopanib (Votrient®) has been approved for various tumors (9). Bevacizumab, the first humanized monoclonal antibody against VEGF-A, was approved by the FDA in 2004. Administration of Bevacizumab, in combination with other chemotherapy agents, showed acceptable anti-tumor efficacy for many solid tumors (10).

Among the recent approaches in cancer immunotherapy, passive immunotherapy including application of blocking monoclonal antibodies or trapping soluble receptors, merely provides a short-lived response, requiring repeated administration of the component; however, active immunotherapy that engages the host immune response is highly desirable, resulting in sustained induction of anti-cancer effects (11, 12). Anti-angiogenic vaccines could be produced based on DNA, peptide, or protein-based structures. Recently, studies focused on VEGF and its receptors as desirable targets to block angiogenesis.

Activation of patients own immune responses would likely introduce less toxicity and side effects than conventional chemotherapeutic medications.

► Please cite this article as:
Soltanpour Gharibdousti F, Fazeli Delshad B, Falak R, Shayanfar N, Ganjalikhani Hakemi M, Andalib A, Kardar GA. Induction of humoral immune responses and inhibition of metastasis in mice by a VEGF peptide-based vaccine. Iran J Basic Med Sci 2020; 23:507-514. doi: 10.22038/ijbms.2020.38508.9141
Therefore, it seems that application of protein- or peptide-based vaccines, in combination with mild doses of radiotherapy, chemotherapy, or other anti-angiogenic agents, may suppress tumor size, growth rate, and metastasis (12-16).

In the present study, we investigated the anti-angiogenic efficacy of a VEGF-A peptide-based vaccine in mice.

**Materials and Methods**

**Immunoinformatics analysis and peptide design**

Amino acid sequences of human VEGF-A (hVEGF₁₆₅ and hVEGF₁₂₁) and mouse VEGF-A (mVEGF₁₆₅ and mVEGF₁₂₀) were retrieved from the UniProt database. Among all isoforms of human VEGF-A, human VEGF₁₆₅ (P15692-4) and VEGF₁₂₁ (P15692-9) were used for peptide design, because they were regarded as major isoforms of human VEGF-A, and showed no significant differences with the sequences of mouse VEGF-A (Q00731-2) and VEGF-A₁₂₀ (Q00731-3) (2). Mega4 alignment software was used to align the isoforms and to find the conserved and similar peptide sequences of human and mice. Among the protected areas, an extracellular 41-mer peptide was selected for determination of T- and B-cell epitopes by Immune Epitope Database Analysis Resources (IEDB). The selected areas were also evaluated for immunogenicity, hydrophilicity, antigenicity, flexibility, and accessibility. Presuming the possible future application of this peptide in human vaccination studies, during sequence selection steps, we considered the major histocompatibility complex (MHC) restriction concept, possible loading of this peptide onto common human leukocyte antigen (HLA) class I and II molecules, especially in the Iranian population with HLA-A*0201 and HLA-DRB1*1103/1104, respectively and its presentation to T cells. Non-overlapping characteristics of the selected sequence with human proteins were determined by protein BLAST. The peptide was then synthesized and attached to Keyhole limpet hemocyanin (KLH) at Selleckchem Company (Selleckchem, USA).

**Animals**

Twenty 6-8-week-old female BALB/c mice were obtained from the animal breeding laboratory of Iran University of Medical Sciences (IUMS), Tehran, Iran, and kept for one week at the animal house to become adapted to study conditions. All procedures were performed under the rules and guidance of the Animal Care Ethical Committee at Isfahan University of Medical Sciences. Mice were divided to four groups of five mice each. The groups were: (1) the vaccine group, which was vaccinated with the KLH-conjugated VEGF-A peptide and challenged with breast cancer-inducing 4T1 cells to evaluate the prophylactic potential of the peptide, (2) the tumor group, which was injected only with 4T1 cells to evaluate the ability of the injected cells to induce tumors, (3) the antibody control group, which was vaccinated only with the KLH-conjugated peptide to evaluate antibody development, and (4) the negative control group, which received only phosphate-buffered saline (PBS).

**Immunization of mice and production of polyclonal antibody**

To induce humoral immune responses, the vaccine and antibody control group mice were injected with 100 μl of a 1 μg/μl solution of the KLH-conjugated peptide without adjuvant on days 1 of weeks 1, 3, and 5 as previously described (17). To boost the antibody titer, the antibody control group received another immunization on day 1 of week 11, too. Sera was collected from all mice before and two weeks after immunizations and stored at -20 °C.

Total IgG was isolated from the antibody control mice sera using an Antibody Purification Kit (Abcam, UK) containing protein G-coupled resin, according to the manufacturer's instructions. The quality of the purification step was determined by SDS-PAGE and silver nitrate staining (18).

**Mouse tumor model**

To determine the prophylactic potency of the conjugated peptide, the vaccine and tumor groups were inoculated subcutaneously four days after the final immunization with 5×10⁵ 4T1 breast cancer cells as previously described (19). In brief, the 4T1 mouse breast cancer cells were cultivated in RPMI media supplemented with 10% fetal bovine serum (FBS). Mice were inoculated subcutaneously into four mammary fat pads on the right side with 5×10⁵ 4T1 cells suspended in 100 μl of PBS. Body weights, clinical symptoms, appearance of fur; and tumor size were recorded every other day. Tumor sizes were calculated using the formula: length×(width)²×0.5 as previously described (19).

**Measurement of serum anti-VEGF titer**

An enzyme-linked immunosorbant assay (ELISA) was used to measure the polyclonal anti-VEGF antibody titer in mice sera. First, 0.5 mg of peptide was conjugated to 2 mg of bovine serum albumin (BSA) using glutaraldehyde reagent as described (20, 21). After dialysis, the final product was analyzed by SDS-PAGE and silver nitrate staining (17-22). For ELISA development, microtiter plates (Maxisorb, Costar, USA) were coated with 100 μl (2 μg/well) of BSA-conjugated peptide in 0.1 M sodium bicarbonate buffer (pH 9.6) overnight at 4 °C. After washing the wells three times with PBS containing 0.05% Tween 20 (PBS-T), the plates were blocked with 2% casein for 2 hr. The plates were then washed twice and 100 μl of serially-diluted serum samples were added and incubated for 2 hr. The wells were then washed five times, and 100 μl of horseradish peroxidase-conjugated sheep anti-mouse IgG (Sigma, USA) were added to each well and incubated for 1 hr. The wells were then washed five times, and 100 μl of TMB (3,3′,5,5′-Tetramethylbenzidine) substrate were added. After 15 min of incubation in the dark, the reaction was stopped with 100 μl of 2 M sulfuric acid and the absorbance was read at 450 nm against a 630 nm reference filter on an ELISA reader. All incubations were performed at 37 °C, except for the coating step.

**Evaluation of inhibitory effects of polyclonal antibodies on HUVEC**

To determine the inhibitory effects of the raised polyclonal antibodies on human VEGF receptor 2 (VEGFR2)-positive cells, human umbilical vein endothelial cells (HUVECs) were cultivated in 96-well
plates (1000 cells/well) with DMEM/F12 medium containing 2% FBS and incubated at 37 °C in 5% CO₂ for 24 hr. Three types of treatments were used. The negative control cells received 0, 25, 50, or 100 ng/ml of recombinant VEGF-A (Sigma, USA). The positive control cells, in addition to VEGF-A, received 100 ng/ml of anti-VEGF monoclonal antibody (Abnova, Taiwan). The test cells, in addition to VEGF-A, received various titers of purified IgG that were isolated from immunized mice. After 48 hr, cell proliferation was evaluated by MTT assay. MTT was added at a concentration of 0.5 mg/ml to each well, and plates were incubated in 5% CO₂ for 4 hr at 37 °C. Formazan crystals were dissolved by adding dimethyl sulfoxide, and after 15 min of incubation at 37 °C the absorbance was measured at 570 nm on a microplate reader.

**Histology**

Hematoxylin and Eosin (H&E)-stained paraffin-embedded tissues were histologically examined for metastases. Three animals from each group were euthanized at the end of week 9 and brains, livers, and lungs were removed, fixed in 4% paraformaldehyde, stained, and examined. Tumor metastases were examined in three random sections and the morphological parameters, indicating metastasis severity were scored from 0-3 (19).

**Statistical analyses**

The student's t-test was used to analyze specific IgG titers and mice body weights. The Mann-Whitney test was used to compare the tumor sizes between the vaccine and control groups. Survival time was analyzed by the Kaplan-Meier method and the groups were compared by the log-rank test. Findings were expressed as means±standard deviations (SDs). Results were considered significant if the P-value of the result was <0.05. All analyses were performed using SPSS version 20.0 (Armonk, New York, USA) and GraphPad Prism 6.0 software (La Jolla, CA, USA).

**Results**

**Immunoinformatics data analysis**

The immunoinformatics study indicated that the selected 41-mer peptide (SNITMQMRKPHQGQHIGEMSFLQHNKCECRPKKDRAQEQ) was sufficiently hydrophilic and antigenic to stimulate the immune system. Based on analysis that was shown in Figure 1, selected sequence in addition to highest rank for B cell epitope has MHC I and II binding epitopes (Figure 1).

**Production and titration of anti-peptide polyclonal antibody**

In the antibody control group mice, after vaccination with KLH-conjugated peptide, the absorbance at 450 nm was significantly greater at weeks 10 and 13 than on initial day of the first week in the 1/100 diluted pooled sera (P<0.05 and P<0.005, respectively), indicating that the anti-VEGF polyclonal antibody titer was significantly greater at weeks 10 and 13 than on day 1 (Figure 2).

Sera were collected from the mice at 5, 7, and 9 weeks after inoculation of the tumor cells and peptide vaccine. Optical densities (ODs) of 1/100 dilutions of these sera were analyzed (Figure 3). At all three time points, the ODs of the vaccine and tumor groups were significantly greater than those of the negative control group (P=0.05 and 0.005, respectively), indicating greater antibody titers in the vaccine and tumor groups than in the negative control group.

**Effects of polyclonal antibody on HUVEC proliferation**

We investigated the effect of purified immunoglobulins from immunized mice sera on proliferation of VEGF-A-treated HUVEC by MTT assay. The negative control,
positive control, and test cells all received 50 ng/ml of recombinant VEGF-A. The positive control cells also received 300 ng/ml of anti-VEGF monoclonal antibody, and the test cells received 80 μg/ml IgG from immunized mice. Proliferation was set at 100% for the negative control cells. Proliferation in the positive control and test cells was significantly lower than in the negative controls (both had \( P<0.001 \)).

**Inhibition of tumor growth in mice**

After injection of 4T1 cells, tumor size was determined in the vaccine and tumor group up to eight weeks. From the second week on, tumors were larger in the tumor group than in the vaccine group, and this difference was statistically significant at eight weeks (\( P<0.001 \)). No tumor growth was observed in the vaccine group from weeks 1-6 (Figure 5).

Five weeks after inoculations with 4T1 cells, three mice from the vaccine and tumor groups were euthanized for tissues examination. Metastases were observed in the lung and liver tissues, primarily in the tumor group mice (Figure 6A and Table 1). In addition, primary tumors in the tumor group were significantly larger than those in the vaccine group (Figure 6B, \( P<0.05 \)).

**Table 1.** Characterization of metastatic properties in lung and liver tissues. Vascularization, necrosis, inflammation, infiltration, and number of detectable metastases in lung and liver are shown

| Mouse ID | Metastatic Tissues | Groups       | Vascularization* | Necrosis** | Inflammation*** | Infiltration % | No. of distinct histologically detectable metastasis |
|---------|-------------------|--------------|------------------|------------|-----------------|---------------|--------------------------------------------------|
| 31      | Lung              | Vaccine      | 0                | 0          | 0               | 0%            | 0                                                |
| 32      |                   |              |                  |            |                 |               | 0                                                |
| 33      |                   |              | +1               | +1         | Mo+             | 40%           | 3                                                |
| 21      |                   | Tumor Only   | +1               | 0          | Mo+             | 40%           | 10                                               |
| 22      |                   |              | +1               | +3         | Mo+             | 70%           | 4                                                |
| 23      |                   |              | +1               | 0          | Mo+             | 60%           | 1                                                |
| 31      | Liver             | Vaccine      | 0                | 0          | 0               | 0%            | 0                                                |
| 32      |                   |              |                  |            |                 |               | 0                                                |
| 33      |                   |              | 0                | 0          | 0               | 0%            | 0                                                |
| 21      |                   | Tumor Only   | +2               | +2         | PMN+            | 40%           | 3                                                |
| 22      |                   |              | +2               | +1         | 0               | 5%            | 12                                               |
| 23      |                   |              | +1               | 0          | 0               | 0%            | 1                                                |

*0 = absence of microscopic neoangiogenesis; 1= moderate neoangiogenesis
**0=no necrosis; 1=moderate; 2=severe
***0=no inflammatory mononuclear and polymorphonuclear cells; Mo+=inflammatory mononuclear cells; PMN+=inflammatory polymorphonuclear cells
Infiltration % = percent of inflammatory cell infiltration
Lung and liver tissues from the vaccine group and tumor group mice were examined by H&E staining and light microscopy. Five weeks after inoculation with 4T1 cells, both lung and liver from the vaccine group mice appeared normal, while lung and liver tissues from the tumor group mice showed metastases, inflammation, necrosis, and infiltration of inflammatory cells. Following necropsy, all mice were examined for metastasis and any other pathological disorders. Fewer metastatic tumors and tumor-related pathologies were found in the lung and liver tissues of vaccine group than tumor group (Table 1). No metastasis was found in the brain tissue of either groups.

**Survival rates of the studied groups**

The survival rates of the vaccine group mice were significantly greater than those of the tumor group mice (P<0.0001). All negative controls survived during the study (Figure 7). Notably, the vaccination steps did not show any side effects. So that, no significant changes were detected in behavior, feeding, body weight or appearance of the studied animals.

**Discussion**

Because growth, expansion, and survival of tumor cells depend on angiogenesis, thus inhibition of angiogenic pathways could be a crucial strategy in cancer treatment (23). Active immunotherapy and vaccine design against VEGF and its receptors still remain topics of interest as therapeutic approaches for inhibition of angiogenesis (24, 25). Nowadays, various tumor-associated therapeutic proteins have been applied to elicit tumor-specific immune responses. One commonly used safe method relies on administration of recombinant peptides in presence or absence of adjuvants. Although these peptides have been shown to induce tumor-targeted immune responses, it seems that the anti-cancer potential of such approaches is limited (26). In 2001, Wei et al. applied the first VEGF-based cancer vaccine in the form of xenogenic DNA to evaluate its anti-tumoral effect on three different tumor models and observed that humoral immune response against VEGF could inhibit primary tumor growth (27). Kamstock et al. developed another xenogenic vaccine against VEGF and evaluated its efficacy in dogs with soft tissue sarcoma. In that study, DNA-liposome complexes were coupled with human VEGF165 and high antibody titers were achieved after immunization with the adjuvant-imbedded protein vaccine (28).

In another study, Rad et al. introduced the VEGF Kinoid vaccine based on human and murine VEGF isoforms. So that, a KLH-conjugated VEGF sequence was used for immunization, and after vaccination of the mice with Freund’s adjuvant, polyclonal anti-VEGF antibody was purified from the mice sera. Afterwards, they examined the inhibitory effect of polyclonal anti-VEGF on human colon carcinoma, as well as mouse and human rhabdiosarcoma; consequently, they concluded that this approach achieved promising results for inhibition of metastasis (29). In another experiment, Gavilando et al. introduced CIGB-247 as a novel protein vaccine. They studied the immunogenicity of this protein in murine, rat, rabbit, and monkey models and reported no unfavorable hematological, biochemical, or histological side effects on the vital organs of the studied animals. This vaccine also did not show any side effects on normal behavior of the animals and demonstrated maintenance of desirable antibody titers after booster doses. This vaccine was a recombinant form of human VEGF, which was expressed in *Escherichia coli* and applied in parallel with small amounts of proteoliposome of the outer cell wall of *Neisseria meningitidis* as adjuvant. Immunization of mice with CIGB-247 significantly reduced tumor growth.
and increased animal survival rate and serum titer of anti-VEGF antibody (14-30). Afterwards, investigations of the safety and immunogenicity of CIGB-247 in human phase I clinical trial initiated and demonstrated some clinical benefits (31).

Kaumaya et al. in 2010 developed a peptide vaccine consisting of synthetic peptides of VEGF as an antigen and T cell epitope of the measles virus fusion protein (MVF) protein as an adjuvant. After evaluation of efficiency of this peptide vaccine on inhibition of VEGFR2 signaling pathway (32), Wang et al. used these synthetic peptide vaccines in murine ovarian cancer model, and the development of high titers of antibody against synthetic peptides was in line with inhibition of angiogenesis in primary tumor models (33).

In 2013, Kyutoku et al. designed DNA vaccine for neutralizing VEGF. For enhancing the immunogenicity of vaccine, hepatitis B virus core (HBc) antigen was considered as an epitope carrier. HBc-VEGF vaccine was evaluated in murine with colon carcinoma and showed humoral immune response that reduced formation of new vessels (34).

Unlike the above studies, the peptide vaccine in our study was designed based on immunogenic structures. Hence, as expected, and as the results of the immunoinformatics analysis showed, the selected peptide, in addition to sufficient antigenicity and ability to stimulate the body’s immune system had the least similarity to other proteins and probably might cause fewer side effects.

Similar to experiments of Rad et al. in 2007, kinoid technology against VEGF was used. KLH was conjugated to the designed peptide to stimulate the immune system and overcome tolerance to VEGF, as a self-antigen. The MTT assay revealed that purified IgG from the peptide-vaccinated mice inhibited VEGF-A-induced HUVEC proliferation, and this result was similar to the inhibitory effect of monoclonal anti-VEGF antibody.

In this study, according to assessment in UniProt and other bioinformatics databases, we chose a 41-mer peptide. This 41-mer sequence was selected from a conserved part of VEGF molecule that did not differ in the amino acid sequence between the human-VEGF and mouse-VEGF. The selected 41-mer peptide stimulated a specific humoral immune response against VEGF. We demonstrated that in silico-designed peptide vaccines can inhibit metastasis in vivo. In addition to monoclonal antibodies, such as Bevacizumab that have adverse side effects and require repeated administrations, cancer vaccines offer promise for cancer patients.

Our results demonstrated that vaccination with a VEGF peptide might produce an antibody response and inhibit primary tumor growth and metastasis.

Although anti-VEGF antibody was produced in the tumor group mice, tumor growth was significantly lower in the vaccine group mice (P<0.001), and no tumor growth was observed in this group until seven weeks after inoculation (Figure 5). In some studies, decreases in tumor growth required multiple immunizations and results were not significant. Gavilando et al. showed decreased tumor growth using six immunizations and three different adjuvants over 36 days following inoculation of mice with cancer cells (11), and Wang et al. showed decreased tumor growth using four immunizations with a VEGF peptide vaccine conjugated to measles virus fusion protein over 45 days after inoculation of mice with cancer cells (28).

To evaluate metastasis, the use of appropriate cancer cell lines with effective invasion and metastatic properties is crucial. Because the immune system plays an important role in the development and progression of tumor, we used BALB/c mice and 4T1 breast cancer cells, which are highly tumorigenic and invasive, and unlike most tumor models, can spontaneously migrate from the primary tumor in the mammary gland to distal sites including lymph nodes, liver, lung, brain, and bone (35, 36).

In this study, by using 4T1 cancer cells, we found less metastasis, necrosis, inflammation, vascularization, and micro-metastatic clones in livers and lungs of the vaccine group than in the tumor group mice (data not shown). Our findings indicate that the antibody response could significantly inhibit metastasis, and the mice showed no metastatic markers. Moreover, no brain metastases were found in the six mice, which were sacrificed five weeks after tumor growth. However, metastasis to liver and lung was obviously severe in the tumor group.

Previous studies showed that multiple immunization and application of adjuvants could decrease the rate of metastasis and increase survival rate, and it could be due to antibody titer rise. Our study was relatively short due to the rapid appearance of tumors and metastases following a single injection with 4T1 cells. In future studies, we will further examine the effects of multiple immunizations and adjuvants. In addition, the presence of a T cell epitope also allowed us to assess immunologic memory. The low survival rates of the mice in this study did not allow sufficient time to observe changes in antibody titers.

Application of an appropriate treatment and considering an optimal strategy for inhibition of tumor growth is a crucial item in cancer therapy. Recent studies have shown that combination therapies, especially combination of immunotherapy with chemotherapy, and usage of immune checkpoint inhibitors can provide hopeful results in clinic (37, 38). In this regard, designing and employing of peptide-based vaccines sounds a promising strategy (39). Therefore, considering the time limitation for hindering possibility of metastasis, it seems that anti-angiogenic vaccination strategies such as immunization against VEGF might be a promising method following initial diagnosis of cancer.

**Conclusion**

We showed that immunization with a VEGF peptide-conjugate can inhibit tumor growth and metastasis in BALB/c mice and might probably increase patient survival rate, too.

**Acknowledgment**

We would like to give our sincere thanks to Dr. James McCoy for precisely editing the manuscript. The results described in this paper were student thesis and was supported by grants number 392552 and 192114 from Isfahan University of Medical Sciences, Isfahan, Iran.
Compliance with Ethical Standards

All animal procedures were performed under the rules and guidance of the Animal Care Ethical Committee of Isfahan University of Medical Sciences, Isfahan, Iran and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards (Ethics code number 192114).

Conflicts of Interest

The authors declare that there are no conflicts of interest.

References

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186.
2. Ramjiawan RR, Griffin AW, Duda DG. Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? Angiogenesis 2017;20:185-204.
3. Tugues S, Koch S, Qualandi L, Li X, Claesson-Welsh L. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. Mol Aspects Med 2011;32:88-111.
4. Carmelit P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473:298-307.
5. Woolard J, Bevan HS, Harper SJ, Bates DO. Molecular diversity of VEGF-A as a regulator of its biological activity. Microcirculation 2009;16:572-592.
6. Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nature Rev Cancer 2008;8:579-591.
7. Heath VL, Bicknell R. Anticancer strategies involving the vasculature. Nature Rev Clin Oncol 2009;6:395-404.
8. Kong DH, Kim MR, Jang JH, Na HJ, Lee S. A review of anti-angiogenic targets for monoclonal antibody cancer therapy. Int J Mol Sci 2017;18: pii: E1786.
9. Matrana MR, Atkinson B, Jonassch E, Tannir NM. Emerging targeted therapies in metastatic renal cell carcinoma. Curr Curr Pharm 2011;6:189-198.
10. Hurvitiz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
11. Emens LA. Cancer vaccines: on the threshold of success. Expert Opin Emerg Drugs 2008;13:295-308.
12. Berzofsky JA, Oh S, Terabe M. Peptide vaccines against cancer. Cancer Treat Res 2005;123:115-136.
13. Morera Y, Bequet-Romero M, Ayala M, Lamdan H, Agger EM, Andersen P, et al. Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjutants. Angiogenesis 2008;11:381-393.
14. Morera Y, Bequet-Romero M, Ayala M, Perez PP, Castro J, Sanchez J, et al. Antigen dose escalation study of a VEGF-based therapeutic cancer vaccine in non human primates. Vaccine 2012;30:368-377.
15. Okiyi Y, Tsuno NH, Saito S, Yoneyama S, Tanaka M, Nagawa H, et al. Vaccines targeting tumour angiogenesis: a novel strategy for cancer immunotherapy. European J Surg Oncol 2006;32:363-370.
16. Gavilondo JV, Hernandez-Bernal F, Ayala-Avila M, de la Torre AV, de la Torre J, Morera-Diaz Y, et al. Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors: results of the CENTAURO antigen dose escalation phase I clinical trial. Vaccine 2014;32:2241-2250.
17. Soltanpour-Gharibdousti F, Kardar GA, Fazeli-Delshad B, Falak R, Ganjali-Bekhami M, Andalib A. Bioinformatic designing for producing vaccine peptide of human vascular endothelial growth factor (VEGF-A), and evaluation of polyclonal antibodies in mice. J Isfahan Med Sch 2016;34:1054-1059.
18. Souldtanlou M, Falak R, Sankian M, Varasteh AR. Generation and characterization of anti-chitinase monoclonal antibodies. Hybridoma 2011;30:145-151.
19. Fazeli-Delshad B, Ganjali-Bekhami M, Soltanpour-Gharibdousti F, Shayanfar N, Falak N, Kardar GA. Evaluation of the functionality of 4T1 cell line in development of metastatic cancer in BALB/c mice as an animal model. Journal of Isfahan Medical School 2016;34:985-990.
20. Briand JP, Muller S, Van Regenmortel MHV. Synthetic peptides as antigens: Pitfalls of conjugation methods. J Immunol Methods 1985;78:59-69.
21. Zegers N, Gerritske D, Deen C, Boersma W, Claassen E. An improved conjugation method for controlled covalent coupling of synthetic peptides to proteins using glutaraldehyde in a dialysis method. J Immunol Methods 1990;130:195-200.
22. Swain M, Ross NW. A silver stain protocol for proteins yielding high resolution and transparent background in sodium dodecyl sulfate-polyacrylamide gels. Electrophoresis 1995;16:948-951.
23. Ichihara E, Kiura K, Tanimoto M. Targeting Angiogenesis in Cancer Therapy. Acta Med Okayama 2011;65:353-62.
24. Bellou S, Penthouardakis G, Murphy C, Fotsis T. Anti-angiogenesis in cancer therapy: Heroes and Hydra. Cancer lett 2013;338:219-228.
25. Suzuki H, Fukuhara M, Yamaura T, Mutoh S, Okabe N, Yamagami H, et al. Multiple therapeutic peptide vaccine consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer. J Transl Med 2013;11:97.
26. Vacchelli E, Martins I, Eggermont A, Friedman W, Galon J, Saués-Fridman C, et al. Trialwatch: Peptide vaccines in cancer therapy. Oncoimmunology 2012;1:1557-1576.
27. Wei YQ, Huang MJ, Yang L, Zhao X, Tian L, Lu Y, et al. Immunogene therapy of tumors with vaccine based on Xenopus homologous vascular endothelial growth factor as a model antigen. Proc Natl Acad Sci USA 2001;98:11545-11550.
28. Kamstock D, Elmslie R, Thamm D, Dow S. Evaluation of a xenogeneic VEGF vaccine in dogs with soft tissue sarcoma. Cancer Immunol Immunother 2007;56:1299-1309.
29. Rad FH, Le Buanec H, Patrunzane S, Larcier P, Genne P, Ryffel B, et al. VEGF kinoid vaccine, a therapeutic approach against tumor angiogenesis and metastases. Proc Natl Acad Sci USA 2007;104:2837-2842.
30. Morera Y, Bequet-Romero M, Ayala M, Velazco JC, Perez PP, Alba JS, et al. Immunogenicity and some safety features of a VEGF-based cancer therapeutic vaccine in rats, rabbits and non-human primates. Vaccine 2010;28:3453-3461.
31. Morera Y, Gonzalez R, Lamdan H, Perez E, Gonzalez Y, Aguero J, et al. Vaccination with a mutated variant of human Vascular Endothelial Growth Factor (VEGF) blocks VEGF-induced retinal neovascularization in a rabbit experimental model. Exp Eye Res 2014;122:102-109.
32. Vicari D, Foy KC, Liotta EM, Kaumaya PT. Engineered conformation-dependent VEGF peptide mimics are effective in inhibiting VEGF signaling pathways. J Biol Chem 2011;286:13612-13625.
33. Wang B, Kaumaya PT, Cohn DE. Immunization with synthetic VEGF peptides in ovarian cancer. Gynecol Oncol 2010;119:564-570.
34. Kyotoku M, Nakagami H, Koriyama H, Tomioka H, Nakagami E, Shimamura M, et al. Development of novel DNA vaccine for VEGF in murine cancer model. Sci Rep 2013;3:3380.
35. Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 1998;58:1486-1493.
36. Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P, et al. A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis 1999;17:163-170.
37. Mawalla B, Yuan X, Luo X, Chalya PL. Treatment outcome of anti-angiogenesis through VEGF-pathway in the management of gastric cancer: a systematic review of phase II and III clinical trials. BMC Res Notes 2018;11:21.
38. Wada S, Yada E, Ohtake J, Sasada T. Personalized peptide vaccines for cancer therapy: current progress and state of the art. Expert Rev Precis Med Drug Dev 2017;2:371-381.
39. Vreeland TJ, Hale DK, Clifton GT, Sears AK, Mittendorf EA and Peoples GE. Peptide vaccine strategies in the treatment of cancer. J Proteomics Bioinform 2013;6:081-084.